Adaptive RAG-Assisted MRI Platform (ARAMP) for Brain Metastasis Detection and Reporting: A Retrospective Evaluation Using Post-Contrast T1-Weighted Imaging.
{"title":"Adaptive RAG-Assisted MRI Platform (ARAMP) for Brain Metastasis Detection and Reporting: A Retrospective Evaluation Using Post-Contrast T1-Weighted Imaging.","authors":"Kuo-Chen Wu, Fatt Yang Chew, Kang-Lun Cheng, Wu-Chung Shen, Pei-Chun Yeh, Chia-Hung Kao, Wan-Yuo Guo, Shih-Sheng Chang","doi":"10.3390/bioengineering12070698","DOIUrl":null,"url":null,"abstract":"<p><p>This study aimed to develop and evaluate an AI-driven platform, the Adaptive RAG Assistant MRI Platform (ARAMP), for assisting in the diagnosis and reporting of brain metastases using post-contrast axial T1-weighted (AX_T1+C) MRI. In this retrospective study, 2447 cancer patients who underwent MRI between 2010 and 2022 were screened. A subset of 100 randomized patients with confirmed brain metastases and 100 matched non-cancer controls were selected for evaluation. ARAMP integrates quantitative radiomic feature extraction with an adaptive Retrieval-Augmented Generation (RAG) framework based on a large language model (LLM, GPT-4o), incorporating five authoritative medical references. Three board-certified neuroradiologists and an independent LLM (Gemini 2.0 Pro) assessed ARAMP performance. Metrics of the assessment included Pre-/Post-Trained Inference Difference, Inter-Inference Agreement, and Sensitivity. Post-training, ARAMP achieved a mean Inference Similarity score of 67.45%. Inter-Inference Agreement among radiologists averaged 30.20% (<i>p</i> = 0.01). Sensitivity for brain metastasis detection improved from 0.84 (pre-training) to 0.98 (post-training). ARAMP also showed improved reliability in identifying brain metastases as the primary diagnosis post-RAG integration. This adaptive RAG-based framework may improve diagnostic efficiency and standardization in radiological workflows.</p>","PeriodicalId":8874,"journal":{"name":"Bioengineering","volume":"12 7","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12292328/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bioengineering","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3390/bioengineering12070698","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
This study aimed to develop and evaluate an AI-driven platform, the Adaptive RAG Assistant MRI Platform (ARAMP), for assisting in the diagnosis and reporting of brain metastases using post-contrast axial T1-weighted (AX_T1+C) MRI. In this retrospective study, 2447 cancer patients who underwent MRI between 2010 and 2022 were screened. A subset of 100 randomized patients with confirmed brain metastases and 100 matched non-cancer controls were selected for evaluation. ARAMP integrates quantitative radiomic feature extraction with an adaptive Retrieval-Augmented Generation (RAG) framework based on a large language model (LLM, GPT-4o), incorporating five authoritative medical references. Three board-certified neuroradiologists and an independent LLM (Gemini 2.0 Pro) assessed ARAMP performance. Metrics of the assessment included Pre-/Post-Trained Inference Difference, Inter-Inference Agreement, and Sensitivity. Post-training, ARAMP achieved a mean Inference Similarity score of 67.45%. Inter-Inference Agreement among radiologists averaged 30.20% (p = 0.01). Sensitivity for brain metastasis detection improved from 0.84 (pre-training) to 0.98 (post-training). ARAMP also showed improved reliability in identifying brain metastases as the primary diagnosis post-RAG integration. This adaptive RAG-based framework may improve diagnostic efficiency and standardization in radiological workflows.
期刊介绍:
Aims
Bioengineering (ISSN 2306-5354) provides an advanced forum for the science and technology of bioengineering. It publishes original research papers, comprehensive reviews, communications and case reports. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. All aspects of bioengineering are welcomed from theoretical concepts to education and applications. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. There are, in addition, four key features of this Journal:
● We are introducing a new concept in scientific and technical publications “The Translational Case Report in Bioengineering”. It is a descriptive explanatory analysis of a transformative or translational event. Understanding that the goal of bioengineering scholarship is to advance towards a transformative or clinical solution to an identified transformative/clinical need, the translational case report is used to explore causation in order to find underlying principles that may guide other similar transformative/translational undertakings.
● Manuscripts regarding research proposals and research ideas will be particularly welcomed.
● Electronic files and software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.
● We also accept manuscripts communicating to a broader audience with regard to research projects financed with public funds.
Scope
● Bionics and biological cybernetics: implantology; bio–abio interfaces
● Bioelectronics: wearable electronics; implantable electronics; “more than Moore” electronics; bioelectronics devices
● Bioprocess and biosystems engineering and applications: bioprocess design; biocatalysis; bioseparation and bioreactors; bioinformatics; bioenergy; etc.
● Biomolecular, cellular and tissue engineering and applications: tissue engineering; chromosome engineering; embryo engineering; cellular, molecular and synthetic biology; metabolic engineering; bio-nanotechnology; micro/nano technologies; genetic engineering; transgenic technology
● Biomedical engineering and applications: biomechatronics; biomedical electronics; biomechanics; biomaterials; biomimetics; biomedical diagnostics; biomedical therapy; biomedical devices; sensors and circuits; biomedical imaging and medical information systems; implants and regenerative medicine; neurotechnology; clinical engineering; rehabilitation engineering
● Biochemical engineering and applications: metabolic pathway engineering; modeling and simulation
● Translational bioengineering